Amneal Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $6.4B
- as of Sep 30, 2026
- Enterprise Value
- $8.8B
- Shares Outstanding
- 319.4M
- Free Float
- 22.9%
Income Statement
- Revenue
- $3.0B
- Operating Income
- $394.1M
- Net Income
- $72.1M
- EBITDA
- $451.4M
- Revenue Growth, 3Y
- 10.9%
- FCF Margin, 3Y Avg
- 10.1%
- FCF Margin, Worst Year
- 8.7%
Cash Flow
- Free Cash Flow
- $269.9M
- FCF Yield
- 4.2%
- Owner FCF Yield
- 3.7%
Balance Sheet
- Cash & Equivalents
- $282.0M
- Total Debt
- $2.7B
- Net Debt
- $2.4B
- Net Debt / EBITDA
- 5.35x
- EV / EBITDA
- 19.59x
- Net Debt / EBIT
- 6.12x
Returns & Capital
- SBC, 3Y Avg
- $28.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $3.0B | $269.9M | 8.9% |
| FY2024 | $2.8B | $243.2M | 8.7% |
| FY2023 | $2.4B | $302.4M | 12.6% |
| FY2022 | $2.2B | $18.7M | 0.8% |
| FY2021 | $2.1B | $194.1M | 9.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 10, 2026
Deals
Amneal Completes Acquisition of Kashiv BioSciences
July 4, 2026
Guidance Season
Chipmakers Lead a Guidance Season Almost Free of Cuts
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 10, 2026
Deals
Amneal Completes Acquisition of Kashiv BioSciences
July 4, 2026
Guidance Season
Chipmakers Lead a Guidance Season Almost Free of Cuts